Table 2.
Live oral rotavirus vaccines under clinical development.
| Candidate | Producer | Strain | Characteristics | Route | Recent findings |
|---|---|---|---|---|---|
| RV3-BB | PT Bio Farma, Indonesia (MCRI, Australia) | Human neonatal G3P[6] | Frozen presentation, ongoing evaluation of a liquid product | Oral | Phase 2a immunogenicity: 76% (New Zealand) |
| Phase 2b immunogenicity & efficacy underway in Indonesia | |||||
| Bovine-human reassortants | Serum Institute of India, Pune | Pentavalent combination (G1-4, G9) | First presentation – lyo, liquid presentation under evaluation | Oral | Phase 3 efficacy of lyophilized product completed, awaiting results |
| G1P[5] G2P[5] G3P[5] G4P[5] G8P[5] G9P[5] and G6P[5] parent strain | Shantha Biotechnic, Hyderabad | Tetravalent combination (G1-4) | Liquid presentation | Oral | Phase 3 non-inferiority study completed |
| Wuhan Institute of Biological Products, China | Hexavalent combination (G1-4, G8, G9) | Liquid presentation | Oral | Phase 1: age descending study approved in China, adult safety completed | |
| Institute Butantan, Brazil | Pentavalent combination (G1-4, G9) | Liquid presentation | Oral | Phase 1 safety in adults completed |